510(k) device
Xpert Xpress CoV-2/Flu plus
Cepheid® · Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF, Class II) · First FDA decision Aug 17, 2023, newest Oct 22, 2026COVID-19, flu and respiratory infections
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
510(k) pathway
Device trials
2
Naming "Xpert Xpress CoV-2"
MAUDE reports
162
Brand "Xpert Xpress CoV-2", since 2015
PubMed studies
24
Mentioning "Xpert Xpress CoV-2"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Xpert Xpress CoV-2/Flu plus
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
K263333 · Decided Oct 22, 2026 · 30 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on DialysisNational analysisReview closedCAG-00413NUpdated Sep 17, 2026
- Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing AgentsNational determinationOn the books150.7Updated Aug 17, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Xpert Xpress CoV-2", any status and sponsor, newest update first.
- Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid TestNot yet recruiting
CorDx, Inc.Not on our public-company list
NCT07875270 · 1,500 participants (planned) · Start Nov 1, 2026 · Primary completion Oct 31, 2027
Device: Flu A/B/COVID-19 + RSV Multiplex Rapid Test · For: SARS-CoV-2 Infection; Influenza A; Influenza B and 1 more
Sites: Alpharetta, Georgia
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Xpert Xpress CoV-2", and for the whole product code for context.
This brand
162 reports: 161 malfunction, 1 injury, 0 death
Whole product code QOF
56 reports: 48 malfunction, 8 injury, 0 death
Newest reports for this brand
- XPERT XPRESS COV-2/FLU/RSV PLUSMalfunction
3004530258-2025-00040 · Received Dec 4, 2025 · Event dated Nov 16, 2025
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF)
Device problem as coded: False Negative Result
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Xpert Xpress CoV-2"[tiab]. The summary above synthesizes these.
- Clinical Evaluation of Xpert Xpress CoV-2/Flu/RSV plus and Alinity m Resp-4-Plex Assay.
Chan WS, Wong KP, Yau SK, et al. · Diagnostics (Basel) · 2024
- Utility of the Xpert Xpress CoV-2/Flu/RSV Plus Kit: A Glance at RSV Infection in Adults and Coinfection Rate.
Alkharsah KR · Saudi J Med Med Sci · 2024
- Rapid Evaluation of the Xpert® Xpress CoV-2 plus and Xpert® Xpress CoV-2/Flu/RSV plus Tests.
Noble LD, Scott LE, Munir R, et al. · Diagnostics (Basel) · 2022
- A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV plus test strategy for the diagnosis of influenza-like illnesses.
Davies S, Boller E, Chase J, et al. · J Med Econ · 2024
- Evaluation of the analytical and clinical performance of two RT-PCR based point-of-care tests; Cepheid Xpert® Xpress CoV-2/Flu/RSV plus and SD BioSensor STANDARDࡊ M10 Flu/RSV/SARS-CoV-2.
Jensen CB, Schneider UV, Madsen TV, et al. · J Clin Virol · 2024Evaluation Study, Comparative Study
- Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs.
Greninger AL, Larcena A, Patel A, et al. · J Clin Microbiol · 2024Multicenter Study, Evaluation Study
- Evaluation of Cepheid Xpert Xpress CoV-2/Flu/RSV plus and the Biofire Spotfire R/ST Panel Mini using CLIA-waived devices.
Hoff JS, Athanasiou Kaatz N, Sabharwal L, et al. · J Clin Virol · 2026Evaluation Study
- Evaluation of Cepheid Xpert Xpress CoV-2/Flu/RSV plus for nasal and nasopharyngeal specimens tested in CLIA-accredited and CLIA-waived settings.
McElvania E, Rao D, Greninger AL, et al. · J Clin Virol · 2025Evaluation Study
- Molecular Detection of Various Non-Seasonal, Zoonotic Influenza Viruses Using BioFire FilmArray and GenXpert Diagnostic Platforms.
Ranadheera C, Chestley T, Perez O, et al. · Viruses · 2025
- Multicenter Clinical Comparison of the 10-Minute AMDI Fast PCR Mini Respiratory Panel and the Cepheid Xpert Xpress CoV-2/Flu/RSV plus.
Srinivasan A, Martin R, Allen G, et al. · J Mol Diagn · 2026Multicenter Study, Comparative Study
- Surveillance of respiratory pathogens: emerging seasonal patterns from western India.
Chheda P, Bhalerao R, Dama T, et al. · Virusdisease · 2026
- When rare becomes common: N2 gene-positive, E gene-negative SARS-CoV-2 PCR results between 2021 and 2022.
Kraus FB, Moritz S, Mamadova K, et al. · J Clin Virol Plus · 2023
Other devices of this type
Also filed under product code QOF.
- BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel MiniBiofire Diagnostics, LLC · 510(k) 2025
- QIAstat-Dx Respiratory Panel PlusQIAGEN GmbH · 510(k) 2025
- Panther Fusion SARS-CoV-2/Flu A/B/RSV assayHologic, Inc. · 510(k) 2024
- BIOFIRE Respiratory Panel 2.1 (RP2.1)Biofire Diagnostics · De Novo 2026
- FINDER Flu A&B/SARS-CoV-2 TestBaebies, Inc. · 510(k) 2026
- Simplexa COVID-19/ Flu A/B & RSV Direct (MOL4450)Diasorin Molecular, LLC · 510(k) 2025
- cobas Respiratory 4-flex for use on the cobas 5800/6800/8800 SystemsRoche Molecular Systems, Inc. · 510(k) 2025
- cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid testRoche Molecular Systems, Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.